Journal article
Depot neuroleptics and manic depressive psychosis
International clinical psychopharmacology, v 1 Suppl 1, pp 53-62
01 Jul 1986
PMID: 3559161
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Twelve patients (eight men and four women) suffering from manic depressive disorder who were receiving both lithium and antipsychotic medication had their antipsychotic changed to depot haloperidol decanoate, with their lithium medication remaining unchanged. Successful transfer to haloperidol decanoate was achieved with a reduced incidence of extrapyramidal side effects, and 100% compliance in eight patients who all remained free of hypomanic relapse, including four patients with rapid-cycling disorder. By comparison, in the three years before switching to haloperidol decanoate these four patients had required sixteen admissions for hypomanic relapses resulting in thirty-four months in-patient treatment.
Metrics
8 Record Views
Details
- Title
- Depot neuroleptics and manic depressive psychosis
- Creators
- M R LoweD H Batchelor
- Publication Details
- International clinical psychopharmacology, v 1 Suppl 1, pp 53-62
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Psychological and Brain Sciences (Psychology)
- Web of Science ID
- WOS:A1986F845800008
- Scopus ID
- 2-s2.0-0022740732
- Other Identifier
- 991019189152904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy
- Psychiatry